MedPath

Safety and Efficacy Study of a New Treatment for Symptoms of Urinary Incontinence

Phase 1
Completed
Conditions
Urinary Incontinence
Interventions
Drug: matching placebo
Registration Number
NCT01340066
Lead Sponsor
Beech Tree Labs, Inc.
Brief Summary

The purpose of this study is to determine if a new drug treatment is effective for the treatment of symptoms of urinary incontinence.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
94
Inclusion Criteria
  • Women who have moderate to severe urge, stress or mixed Urinary Incontinence
Exclusion Criteria
  • Medical history of migraines, neurologic problems, swallowing disorder, stroke or severe depression.
  • Medical history of heart failure, peripheral edema or moderate to severe asthma or chronic obstructive pulmonary disease (COPD)
  • Certain restricted medications
  • Any other condition that would interfere with the safety of the subject

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Matching placebomatching placebo-
UISH001UISH001-
Primary Outcome Measures
NameTimeMethod
Percentage of Participants With a Decrease in Leakage Events of 30% or More.Change from baseline after 4 weeks of treatment.

Incontinence events were recorded on a daily diary. Leaks were scored and tabulated for a daily score. These values were utilized to come up with total of leakage events during the double-blind treatment period.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (3)

Regional Clinical Research, Inc.

🇺🇸

Endwell, New York, United States

Rochester Clinical Research

🇺🇸

Rochester, New York, United States

PEAK Research, LLC

🇺🇸

Upper St. Clair, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath